• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research.血清胃蛋白酶原在中国健康体检人群中诊断萎缩性胃炎的潜在价值:一项诊断性临床研究
BMC Gastroenterol. 2017 Jul 20;17(1):88. doi: 10.1186/s12876-017-0641-6.
2
The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.中国组织学胃炎分期-“OLGA/OLGIM”与血清胃蛋白酶原检测在评估胃萎缩/肠化生中的相关性
Scand J Gastroenterol. 2017 Aug;52(8):822-827. doi: 10.1080/00365521.2017.1315739. Epub 2017 Apr 22.
3
The application of new gastric cancer screening score system for gastric cancer screening and risk assessment of gastric precancerous lesions in China.新型胃癌筛查评分系统在中国胃癌筛查及癌前病变风险评估中的应用
Scand J Gastroenterol. 2023 Jan;58(1):34-37. doi: 10.1080/00365521.2022.2099761. Epub 2022 Jul 22.
4
[Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].[血清胃蛋白酶原水平作为萎缩性胃炎筛查试验的临床应用]
Korean J Lab Med. 2008 Jun;28(3):201-6. doi: 10.3343/kjlm.2008.28.3.201.
5
Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel Test.血清生物标志物 panel 在萎缩性胃炎和胃镜转诊患者感染诊断中的应用:新一代 GastroPanel 试验的临床验证。
Anticancer Res. 2021 Nov;41(11):5527-5537. doi: 10.21873/anticanres.15366.
6
Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies.通过血清胃蛋白酶原、胃泌素-17和幽门螺杆菌免疫球蛋白G抗体筛查萎缩性胃炎和胃癌。
J Dig Dis. 2007 Feb;8(1):15-22. doi: 10.1111/j.1443-9573.2007.00271.x.
7
Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.血浆胃饥饿素浓度与血清胃蛋白酶原I水平及胃蛋白酶原I/II比值相关——一种可能的新型非侵入性胃萎缩标志物。
Hepatogastroenterology. 2004 Sep-Oct;51(59):1249-54.
8
Diagnostic Value of Serum Pepsinogen Levels for Screening Gastric Cancer and Atrophic Gastritis in Asymptomatic Individuals: A Cross-Sectional Study.血清胃蛋白酶原水平对无症状个体胃癌及萎缩性胃炎筛查的诊断价值:一项横断面研究
Front Oncol. 2021 Aug 24;11:652574. doi: 10.3389/fonc.2021.652574. eCollection 2021.
9
Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.幽门螺杆菌状态与血清胃蛋白酶原作为萎缩性胃炎血清学标志物之间的关系
Turk J Gastroenterol. 2006 Sep;17(3):172-6.
10
Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea.韩国健康体检人群中胃蛋白酶原检测和幽门螺杆菌血清学的临床意义。
Eur J Gastroenterol Hepatol. 2009 Jun;21(6):606-12. doi: 10.1097/MEG.0b013e3283086757.

引用本文的文献

1
Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.血清胃蛋白酶原作为胃胃肠道间质瘤(GIST)的生物标志物
Cancer Med. 2025 Sep;14(17):e71186. doi: 10.1002/cam4.71186.
2
The potential value of serum pepsinogen and gastrin-17 for the diagnosis of chronic atrophic gastritis at different stages of severity: a clinical diagnostic study.血清胃蛋白酶原和胃泌素-17在不同严重程度慢性萎缩性胃炎诊断中的潜在价值:一项临床诊断研究
BMC Gastroenterol. 2025 Jun 4;25(1):428. doi: 10.1186/s12876-025-03996-8.
3
A Proton Pump Inhibitor Independently Elevates Gastrin Levels as a Marker for Metachronous Gastric Cancer After Endoscopic Submucosal Dissection.质子泵抑制剂可独立升高胃泌素水平,作为内镜黏膜下剥离术后异时性胃癌的标志物。
J Clin Med. 2024 Nov 3;13(21):6599. doi: 10.3390/jcm13216599.
4
Serum pepsinogen level as a biomarker for atrophy, reflux esophagitis, and gastric cancer screening in Indonesia.血清胃蛋白酶原水平作为印度尼西亚萎缩、反流性食管炎和胃癌筛查的生物标志物。
J Res Med Sci. 2022 Dec 23;27:90. doi: 10.4103/jrms.jrms_983_21. eCollection 2022.
5
Analysis of high risk factors for chronic atrophic gastritis.分析慢性萎缩性胃炎的高危因素。
Saudi J Gastroenterol. 2023 Mar-Apr;29(2):127-134. doi: 10.4103/sjg.sjg_383_22.
6
Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer.胃癌诊断与治疗的最新趋势及进展
Cancers (Basel). 2022 Nov 15;14(22):5615. doi: 10.3390/cancers14225615.
7
Serum pepsinogen: A potential non-invasive screening method for moderate and severe atrophic gastritis among an asian population.血清胃蛋白酶原:一种针对亚洲人群中重度萎缩性胃炎的潜在非侵入性筛查方法。
Ann Med Surg (Lond). 2022 May 27;78:103844. doi: 10.1016/j.amsu.2022.103844. eCollection 2022 Jun.
8
Atrophic gastritis is inversely associated with gastroesophageal reflux disease in a twin register based study.萎缩性胃炎与基于双胞胎登记的胃食管反流病呈负相关。
United European Gastroenterol J. 2022 Oct;10(8):827-835. doi: 10.1002/ueg2.12267. Epub 2022 Jun 22.
9
Factors Associated with False Negative Results in Serum Pepsinogen Testing for Precancerous Gastric Lesions in a European Population in the GISTAR Study.GISTAR研究中欧洲人群胃癌前病变血清胃蛋白酶原检测假阴性结果的相关因素
Diagnostics (Basel). 2022 May 7;12(5):1166. doi: 10.3390/diagnostics12051166.
10
Research progress on exosomal proteins as diagnostic markers of gastric cancer (review article).外泌体蛋白作为胃癌诊断标志物的研究进展(综述文章)。
Clin Exp Med. 2023 Jun;23(2):203-218. doi: 10.1007/s10238-022-00793-5. Epub 2022 Jan 22.

本文引用的文献

1
Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel®) in St. Petersburg.圣彼得堡基于血清生物标志物检测板(GastroPanel®)进行的人群筛查中幽门螺杆菌感染和萎缩性胃炎的患病率
Anticancer Res. 2016 Aug;36(8):4129-38.
2
Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA.中国和美国幽门螺杆菌感染患病率时间趋势的系统评价。
Gut Pathog. 2016 Mar 15;8:8. doi: 10.1186/s13099-016-0091-7. eCollection 2016.
3
Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis.血清胃蛋白酶原作为胃癌和萎缩性胃炎筛查生物标志物的意义:一项系统评价和荟萃分析
PLoS One. 2015 Nov 10;10(11):e0142080. doi: 10.1371/journal.pone.0142080. eCollection 2015.
4
Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population.胃蛋白酶原在伊朗人群中对萎缩性胃炎和胃癌早期诊断的准确性。
Med J Islam Repub Iran. 2014 Dec 16;28:150. eCollection 2014.
5
Endoscopic gastric cancer screening and surveillance in high-risk groups.高危人群的内镜下胃癌筛查与监测
Clin Endosc. 2014 Nov;47(6):497-503. doi: 10.5946/ce.2014.47.6.497. Epub 2014 Nov 30.
6
Gastric cancer: prevention, screening and early diagnosis.胃癌:预防、筛查与早期诊断
World J Gastroenterol. 2014 Oct 14;20(38):13842-62. doi: 10.3748/wjg.v20.i38.13842.
7
Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study.幽门螺杆菌根除与胃癌及胃黏膜组织学变化的关系:一项10年随访研究
Chin Med J (Engl). 2014;127(8):1454-8.
8
Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers.哈萨克斯坦有症状和消化不良的成年人群中 H. pylori 感染和萎缩性胃炎的流行情况。一项使用血清生物标志物小组进行的基于医院的筛查研究。
Anticancer Res. 2013 Oct;33(10):4595-602.
9
Precancerous lesions in the stomach: from biology to clinical patient management.胃前病变:从生物学到临床患者管理。
Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):205-23. doi: 10.1016/j.bpg.2012.12.007.
10
Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study.血清胃蛋白酶原水平预测胃癌发病率的最佳临界值:久山研究
Scand J Gastroenterol. 2012 Jun;47(6):669-75. doi: 10.3109/00365521.2012.658855. Epub 2012 Mar 20.

血清胃蛋白酶原在中国健康体检人群中诊断萎缩性胃炎的潜在价值:一项诊断性临床研究

The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research.

作者信息

Tong Yuling, Wu Yulian, Song Zhenya, Yu Yingying, Yu Xinyan

机构信息

International HealthCare Center, The Second Affiliated Hospital of Zhejiang University, School of Medicine, NO.88 Jiefang Road, Hangzhou, Zhejiang Province, People's Republic of China.

General Surgery Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, NO.88 Jiefang Road, Hangzhou, Zhejiang Province, People's Republic of China.

出版信息

BMC Gastroenterol. 2017 Jul 20;17(1):88. doi: 10.1186/s12876-017-0641-6.

DOI:10.1186/s12876-017-0641-6
PMID:28728545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5520218/
Abstract

BACKGROUND

The aim of this study is to assess the validity of the measurement of pepsinogen as a screening test for chronic atrophic gastritis (AG) in health check-up populations in China.

METHODS

Patients from consecutive regular health check-up were enrolled from January 2014 to June 2015. Endoscopy, combined with monitoring the Helicobacter pylori (Hp) infections, and measuring the serum pepsinogen (PG) were used to determine the diagnostic accuracy of PG for the screening of atrophic gastritis. Histopathology was assessed by the Operative Link on Gastritis Assessment (OLGA) system. Statistical analysis was performed using SPSS statistical software.

RESULTS

The total Hp infection rate was 40%. Based on pathology, the 996 participants were divided into three groups: non-atrophic (NAG), mild-moderate atrophic (MAG): stage I and II of the OLGA classification, and severe atrophic (SAG): stage III and IV of the OLGA classification. Compared with NAG and MAG groups, PGR decreased significantly in SAG group (p < 0.05). PGI and PGII levels were significantly elevated in Hp-positive group, while the PGR was markedly decreased (p < 0.01). When MAG and SAG groups were combined and compared with NAG group, the best cutoff value for atrophy diagnosis was PGI ≤50.3 ng/ml; the cutoff value in Hp-negative group was absolutely higher than in Hp-positive group. When NAG and MAG groups were combined and compared with the SAG group, the best cutoff value for diagnosis of severe atrophy was at PGR ≤4.28. The cutoff values in Hp-negative and Hp-positive groups were calculated at PGR ≤6.28 and ≤4.28, respectively.

CONCLUSIONS

Pepsinogens play an important role in the identification of patients with atrophic gastritis and severe AG. Use of different cutoff values of PG for Hp-negative and Hp-positive groups may offer greater efficacy in the diagnosis of AG.

摘要

背景

本研究旨在评估在中国健康体检人群中,胃蛋白酶原检测作为慢性萎缩性胃炎(AG)筛查试验的有效性。

方法

选取2014年1月至2015年6月期间连续进行常规健康体检的患者。采用内镜检查,并监测幽门螺杆菌(Hp)感染情况,同时检测血清胃蛋白酶原(PG),以确定PG筛查萎缩性胃炎的诊断准确性。通过胃炎评估手术链接(OLGA)系统进行组织病理学评估。使用SPSS统计软件进行统计分析。

结果

Hp总感染率为40%。根据病理结果,996名参与者被分为三组:非萎缩性(NAG)、轻度-中度萎缩性(MAG):OLGA分类的I期和II期,以及重度萎缩性(SAG):OLGA分类的III期和IV期。与NAG组和MAG组相比,SAG组的PGR显著降低(p<0.05)。Hp阳性组的PGI和PGII水平显著升高,而PGR显著降低(p<0.01)。当MAG组和SAG组合并与NAG组比较时,萎缩诊断的最佳临界值为PGI≤50.3 ng/ml;Hp阴性组的临界值绝对高于Hp阳性组。当NAG组和MAG组合并与SAG组比较时,重度萎缩诊断的最佳临界值为PGR≤4.28。Hp阴性组和Hp阳性组的临界值分别计算为PGR≤6.28和≤4.28。

结论

胃蛋白酶原在萎缩性胃炎和重度AG患者的识别中起重要作用。针对Hp阴性和Hp阳性组使用不同的PG临界值可能在AG诊断中具有更高的效能。